Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of GQ1005 versus trastuzumab emtansine in previously trastuzumab- and taxane-treated HER2-positive unresectable or metastatic breast cancer
CTR20244790Phase 3Active
- Sponsor
- GeneQuantum Biosciences
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gq1005 in breast cancer, sponsored by GeneQuantum Biosciences. Started Jan 2025; status: active.
02
Drugs
gq1005
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20244790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244790.